Skip to main content
Clinical Trials/NCT07274163
NCT07274163
Recruiting
Not Applicable

Ambispective Registry of Patients Affected by Lung Cancer

Fondazione IRCCS Policlinico San Matteo di Pavia1 site in 1 country1,500 target enrollmentStarted: January 1, 2019Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
1,500
Locations
1
Primary Endpoint
10 years overall survival

Overview

Brief Summary

Lung cancer is one of the most common cancers and the leading cause of cancer-related death. It is often diagnosed late, and there are different types of lung cancer. Today, many patients benefit from targeted therapies and immunotherapy, which have improved survival.

This study will create an ambispective clinical registry of all lung cancer patients treated at Policlinico San Matteo.

The registry will collect data from 2019 to 2035 to better understand: 10-year overall survival, how the disease progresses over time, how patients respond to treatments and possible side effects, how patient and tumor characteristics influence treatment choices, how different therapies work in real-world practice.

All data will be securely collected whithin REDCap platform and used to improve future care and research.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients ≥ 18 years diagnosed with and/or treated for lung cancer at the department of SC Oncologia 1 Unit of the Fondazione IRCCS Policlinico San Matteo;
  • Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document;
  • Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease.

Exclusion Criteria

  • Patients who are unable to understand informed consent document.

Outcomes

Primary Outcomes

10 years overall survival

Time Frame: 10 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Francesco Agustoni

Principal Investigator

Fondazione IRCCS Policlinico San Matteo di Pavia

Study Sites (1)

Loading locations...

Similar Trials